Literature DB >> 1430155

Central nervous system demyelination and remyelination in multiple sclerosis and viral models of disease.

M Rodriguez1.   

Abstract

The mechanisms of myelin injury and repair were studied in acute multiple sclerosis lesions and in a murine model of demyelination induced by a virus. Injury to oligodendrocytes resulting in degeneration of inner glial loops and inner myelin lamellae (dying-back oligodendrogliopathy) was observed by electron microscopy in brain biopsies of acute demyelinating lesions. Attempts at central nervous system remyelination as manifested by thinly myelinated axons and proliferation of oligodendrocytes were observed at the edge of many acute plaques. To develop therapeutic strategies to inhibit demyelination or promote remyelination, mice infected intracranially with Theiler's virus (a picornavirus) were studied. Experimental manipulation of Theiler's virus-infected mice by treatment during chronic demyelinating disease with immunoglobulins directed at normal spinal cord antigens or with monoclonal antibodies which deplete CD4 or CD8-positive T cells resulted in augmentation of new myelin synthesis. These observations suggest that disturbances in the myelinating function of oligodendrocytes, events not accompanied by death of these cells, may be among the earliest pathological events in multiple sclerosis. Experiments using the Theiler's virus model of demyelination indicate that manipulation of the immune response has the potential to promote central nervous system remyelination and functional recovery in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430155     DOI: 10.1016/0165-5728(92)90141-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  A transgenic mouse model for inducible and reversible dysmyelination.

Authors:  C Mathis; C Hindelang; M LeMeur; E Borrelli
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Non-AUG-initiated internal translation of the L* protein of Theiler's virus and importance of this protein for viral persistence.

Authors:  Olivier van Eyll; Thomas Michiels
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 3.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  A quantitative morphometric analysis of rat spinal cord remyelination following transplantation of allogenic Schwann cells.

Authors:  Karen L Lankford; Toshio Imaizumi; Osamu Honmou; Jeffery D Kocsis
Journal:  J Comp Neurol       Date:  2002-02-11       Impact factor: 3.215

Review 5.  Do oligodendrocytes divide?

Authors:  W T Norton
Journal:  Neurochem Res       Date:  1996-04       Impact factor: 3.996

6.  Short-term cuprizone feeding verifies N-acetylaspartate quantification as a marker of neurodegeneration.

Authors:  Barbara Maria Krauspe; Wolfgang Dreher; Cordian Beyer; Werner Baumgartner; Bernd Denecke; Katharina Janssen; Claus-Dieter Langhans; Tim Clarner; Markus Kipp
Journal:  J Mol Neurosci       Date:  2014-09-05       Impact factor: 3.444

Review 7.  The pathology of multiple sclerosis and its evolution.

Authors:  H Lassmann
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

8.  Loss of myelin-associated glycoprotein in kearns-sayre syndrome.

Authors:  Nichola Z Lax; Graham R Campbell; Amy K Reeve; Nobuhiko Ohno; Jessica Zambonin; Emma L Blakely; Robert W Taylor; Eduardo Bonilla; Kurenai Tanji; Salvatore DiMauro; Evelyn Jaros; Hans Lassmann; Doug M Turnbull; Don J Mahad
Journal:  Arch Neurol       Date:  2012-04

Review 9.  A unified cell biological perspective on axon-myelin injury.

Authors:  Mikael Simons; Thomas Misgeld; Martin Kerschensteiner
Journal:  J Cell Biol       Date:  2014-08-04       Impact factor: 10.539

Review 10.  Hypoxia-like tissue injury as a component of multiple sclerosis lesions.

Authors:  Hans Lassmann
Journal:  J Neurol Sci       Date:  2003-02-15       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.